The DTNBP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the DTNBP1 gene in the HT29 cell line. DTNBP1 encodes dysbindin, a core subunit of the BLOC-1 complex essential for lysosome-related organelle biogenesis and synaptic vesicle trafficking. This polyclonal pool provides a heterogeneous loss-of-function model, avoiding clonal selection biases and enabling robust study of dysbindin deficiency in a human epithelial colorectal adenocarcinoma background.
HT29 cells are a widely used human colorectal adenocarcinoma line, pivotal for intestinal epithelial biology, drug absorption studies, and cancer research. They exhibit key epithelial features, including mucin production and tight junction formation, and provide a genetically tractable system. Importantly, HT29 cells express components of the BLOC-1 complex, making them a relevant non-neuronal host for investigating dysbindin-dependent trafficking and cellular processes.
Dysbindin functions as a central scaffold within the BLOC-1 complex, interacting with subunits such as BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S4, BLOC1S5, and BLOC1S6, as well as dystrobrevin, snapin, muted, and pallidin. It is transcriptionally regulated by PAX6 and functions downstream of dystrobrevin signaling. Dysbindin modulates key downstream targets, including SNARE proteins, RAB GTPases, and actin cytoskeleton regulators, thereby coordinating lysosomal transport and synaptic vesicle release. Disruption of DTNBP1 impairs these processes, contributing to neurological conditions like schizophrenia and Hermansky-Pudlak syndrome type 7, as well as broader cellular dysfunction.
In the HT29 background, knockout of DTNBP1 provides a unique model to dissect dysbindin-dependent trafficking in epithelial cancer biology. Dysbindin influences actin cytoskeleton organization and receptor trafficking, processes central to cell migration, invasion, and drug sensitivity. This model permits investigation of how BLOC-1 complex dysfunction affects lysosomal biogenesis and autophagic flux in colorectal adenocarcinoma, linking organelle trafficking to cancer progression. The polyclonal nature of the knockout population also mirrors genetic heterogeneity, offering a physiologically relevant system for functional genomics and drug screening.
Research applications for the DTNBP1 Knockout HT29 Polyclonal Cells span vesicular trafficking assays to dissect BLOC-1-dependent transport, co-immunoprecipitation studies to map protein interaction networks, and immunofluorescence localization of organelle markers. In cancer biology, migration and invasion assays, as well as drug sensitivity studies, can assess dysbindin’s role in metastatic potential. The cells are also suitable for neurotransmitter release measurements to examine conserved synaptic vesicle release machinery. For further information, contact Ascent Research.
